文献速递脑血管病

既往抗血小板治疗对急性卒中血管内治疗结局的影响

Impact of Prior Antiplatelet Therapy on Outcomes After Endovascular Therapy for Acute Stroke: Endovascular Treatment in Ischemic Stroke Registry Results.
PubMed 文献 · Stroke · 2021-09-20

基于法国Endovascular Treatment in Ischemic Stroke前瞻性多中心登记,分析2939例接受血管内治疗的急性缺血性卒中患者,其中877例(29.8%)有既往抗血小板治疗。调整混杂因素后,既往抗血小板治疗与完全再灌注率、围术期并发症、症状性颅内出血、3个月良好功能结局及90天死亡率均无显著关联。

要点

  • 既往抗血小板治疗不影响血管内治疗后的血管造影和功能结局。
  • 既往抗血小板治疗不应影响急性血运重建策略的决策。
  • 两组症状性颅内出血和90天死亡率无显著差异。

核心结论

  • 既往抗血小板治疗不影响急性缺血性卒中血管内治疗后的血管造影和功能结局,不应作为急性血运重建策略的考量因素。

研究设计与样本

  • 分析法国正在进行的Endovascular Treatment in Ischemic Stroke前瞻性多中心登记中2939例接受血管内治疗的急性缺血性卒中患者,分为既往抗血小板治疗组(877例,29.8%)和无既往抗血小板治疗组。

主要发现

  • 完全再灌注率在无既往抗血小板组为37.9%,既往抗血小板组为42.7%,aOR 1.09(95% CI 0.88-1.34),P=0.41。
  • 围术期并发症发生率在无既往抗血小板组为16.9%,既往抗血小板组为13.3%,aOR 0.90(95% CI 0.7-1.2),P=0.66。
  • 症状性颅内出血的aOR为0.93(95% CI 0.63-1.37),P=0.73。
  • 3个月良好临床结局(改良Rankin量表评分0-2)的aOR为0.98(95% CI 0.77-1.25),P=0.89。
  • 90天死亡率的aOR为0.95(95% CI 0.72-1.26),P=0.76。

临床怎么用

  • 对于既往使用抗血小板药物的急性缺血性卒中患者,血管内治疗决策无需因既往抗血小板治疗而改变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The influence of prior antiplatelet therapy (APT) uses on the outcomes of patients with acute ischemic stroke treated with endovascular therapy is unclear. We compared procedural and clinical outcomes of endovascular therapy in patients on APT or not before stroke onset. METHODS: We analyzed 2 groups from the ongoing prospective multicenter Endovascular Treatment in Ischemic Stroke registry in France: patients on prior APT (APT+) and patients without prior APT (APT-) treated by endovascular therapy, with and without intravenous thrombolysis. Multilevel mixed-effects logistic models including center as random effect were used to compare angiographic (rates of reperfusion at the end of procedure, procedural complications) and clinical (favorable and excellent outcome, 90-day all-cause mortality, and hemorrhagic complications) outcomes according to APT subgroups. Comparisons were adjusted for prespecified confounders (age, admission National Institutes of Health Stroke Scale score, Alberta Stroke Program Early CT Score, intravenous thrombolysis, and time from onset to puncture), as well as for meaningful baseline between-group differences. RESULTS: A total of 2939 patients were analyzed, of whom 877 (29.8%) were on prior APT. Patients with prior APT were older, had more frequent vascular risk factors, cardioembolic stroke mechanism, and prestroke disability. Rates of complete reperfusion (37.9% in the APT- group versus 42.7 % in the APT+ group; aOR, 1.09 [95% CI, 0.88-1.34]; P=0.41) and periprocedural complication (16.9% versus 13.3%; aOR, 0.90 [95% CI, 0.7-1.2]; P=0.66) did not differ between the two groups. Symptomatic intracerebral hemorrhage (aOR, 0.93 [95% CI, 0.63-1.37]; P=0.73), 3 months favorable clinical outcome (modified Rankin Scale score of 0-2; aOR, 0.98 [95% CI, 0.77-1.25]; P=0.89), and mortality (aOR, 0.95 [95% CI, 0.72-1.26]; P=0.76) at 90 days did not differ between the groups. CONCLUSIONS: Prior APT does not influence angiographic and functional outcomes following endovascular therapy and should not be taken into account for acute revascularization strategies.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Couture M, Finitsis S, Marnat G, et al. Impact of Prior Antiplatelet Therapy on Outcomes After Endovascular Therapy for Acute Stroke: Endovascular Treatment in Ischemic Stroke Registry Results. Stroke. 2021. PMID: 34538083. doi:10.1161/STROKEAHA.121.034670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。